Analysts Offer Predictions for C4 Therapeutics Q2 Earnings

C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Equities research analysts at Brookline Capital Management reduced their Q2 2025 earnings per share (EPS) estimates for shares of C4 Therapeutics in a report issued on Wednesday, May 7th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of ($0.43) per share for the quarter, down from their previous estimate of ($0.39). The consensus estimate for C4 Therapeutics' current full-year earnings is ($1.52) per share. Brookline Capital Management also issued estimates for C4 Therapeutics' Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.79) EPS, FY2026 earnings at ($2.20) EPS and FY2027 earnings at ($2.32) EPS.

Separately, UBS Group raised shares of C4 Therapeutics to a "hold" rating in a research report on Friday, February 14th.

C4 Therapeutics Price Performance

Shares of NASDAQ CCCC traded down $0.13 during trading hours on Monday, hitting $1.37. 680,798 shares of the company's stock were exchanged, compared to its average volume of 1,396,149. The company's 50-day moving average price is $1.64 and its 200-day moving average price is $3.17. The stock has a market capitalization of $97.28 million, a price-to-earnings ratio of -0.81 and a beta of 3.10. C4 Therapeutics has a 1-year low of $1.09 and a 1-year high of $7.66.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.11. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. The business had revenue of $7.20 million for the quarter, compared to analyst estimates of $3.54 million.

Institutional Trading of C4 Therapeutics

Institutional investors have recently modified their holdings of the company. Intech Investment Management LLC boosted its holdings in C4 Therapeutics by 11.1% during the fourth quarter. Intech Investment Management LLC now owns 30,150 shares of the company's stock valued at $109,000 after purchasing an additional 3,024 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in C4 Therapeutics by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 486,366 shares of the company's stock worth $1,751,000 after acquiring an additional 3,437 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of C4 Therapeutics by 4.6% during the fourth quarter. Rhumbline Advisers now owns 100,015 shares of the company's stock valued at $360,000 after acquiring an additional 4,366 shares during the period. Invesco Ltd. lifted its holdings in shares of C4 Therapeutics by 7.2% during the fourth quarter. Invesco Ltd. now owns 69,193 shares of the company's stock valued at $249,000 after acquiring an additional 4,647 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of C4 Therapeutics by 1.1% during the fourth quarter. Northern Trust Corp now owns 495,043 shares of the company's stock valued at $1,782,000 after acquiring an additional 5,223 shares during the period. Institutional investors and hedge funds own 78.81% of the company's stock.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.